ArticleCommunications medicine2023
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV.
Article in Communications medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis.Epidemiology and infection · 2023Pooled it
- Serological response following COVID-19 vaccines in patients living with HIV: a dose-response meta-analysis.Scientific reports · 2023Pooled it
- Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndrome.Human vaccines & immunotherapeutics · 2026Article
- Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.Journal of translational medicine · 2025Article
- Severe acute respiratory syndrome coronavirus-2 antibody prevalence in adults with HIV.AIDS (London, England) · 2025Article
- Machine learning approaches to dissect hybrid and vaccine-induced immunity.Communications medicine · 2025Article
- Transcriptomic analysis after SARS-CoV-2 mRNA vaccination reveals a specific gene signature in low-responder hemodialysis patients.Frontiers in immunology · 2025Article
- The Impact of HIV on B Cell Compartment and Its Implications for COVID-19 Vaccinations in People with HIV.Vaccines · 2024Review
- Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach.Journal of translational medicine · 2024Observational
- The immune response to SARS-CoV-2 in people with HIV.Cellular & molecular immunology · 2024Review
- Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?Microorganisms · 2023Article
- The Humoral Response to SARS-CoV-2 Vaccine in Hemodialysis Patients Is Correlated with Nutritional Status.Vaccines · 2023Article
- Article
- Correlation between CD4 T-Cell Counts and Seroconversion among COVID-19 Vaccinated Patients with HIV: A Meta-Analysis.Vaccines · 2023Review
- Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.Frontiers in immunology · 2023Article
- Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited longitudinal data are available on immune response to mRNA SARS-CoV-2 vaccination in people living with HIV (PLWHIV); therefore, new evidence on induction and persistence of spike-specific antibodies and B cells is needed.
methodsIn this pilot study we investigated the spike-specific humoral and B cell responses up to six months after vaccination with two doses of mRNA vaccines in 84 PLWHIV under antiretroviral therapy compared to 79 healthy controls (HCs).
resultsSpike-specific IgG persisted six months in PLWHIV with no significant differences compared to HCs, even though a significantly lower IgG response was observed in patients with CD4
conclusionsThe mRNA vaccination against SARS-CoV-2 elicits humoral and B cell responses quantitatively similar between PLWHIV and HCs, but there are important differences in terms of antibody functionality and phenotypes of memory B cells, reinforcing the notion that tailored vaccination policies should be considered for these patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.